Research & Development
IncellDx launches long-COVID test for European markets
The firm said it developed the test based on clinical studies published in Frontiers in Immunology showing that its researchers generated disease scores specifically for long COVID. The researchers used machine learning and artificial intelligence to measure and analyze cytokines and chemokines -- sets of inflammatory markers.
August 30, 2022
Pharos Capital sells TechLab to SSI Diagnostica
TechLab produces tests for infectious diseases, intestinal inflammation, and parasites, as well as gastrointestinal conditions such as inflammatory bowel disease, irritable bowel syndrome, and Escherichia coli infection. It also offers a test for Clostridioides difficile called Quik Chek, according to Pharos Capital.
August 21, 2022
Metabolon, Mayo Clinic ink joint development agreement
Metabolon will analyze patient clinical samples from multiple cohorts to identify disease biomarkers that Mayo Clinic would use to develop diagnostic tests.
August 8, 2022
Detecting SARS-CoV-2 in blood may be early indicator of severe disease
With the original SARS-CoV virus, high serum viral load and detection of the virus at multiple sites were predictive of adverse clinical outcomes. With SARS-CoV-2, increased oropharyngeal (throat) viral loads have been associated with age. Disease severity has been suggested to be correlated to SARS-CoV-2 RNA detected in serum. The inability to control viral replication can lead to spread of infection to multiple organs, possibly causing severe disease and driving excessive inflammatory reactions.
September 1, 2020
Thermo Fisher teams with Owlstone on breath tests
Based in Cambridge, U.K., Owlstone offers its Breath Biopsy platform and developed the ReCiva breath sampler for collecting "volatile organic compounds" in breath, enabling chemical analysis and an understanding of underlying metabolic processes. The company sees the breathalyzer as being applicable across conditions, but it has focused its research on cancer, inflammatory disease, and infectious disease.
November 6, 2019
Gene panel finds root of neuroinflammatory symptoms in kids
Neuroinflammatory conditions -- severe disorders in the brain and spine -- are increasingly common in pediatric patients and may manifest as seizures, encephalopathy, focal motor deficits, and other symptoms. But the causes are diverse, which presents a challenge for identification and could lead to delays in diagnosis. A monogenic disease may be at the root of the problem, but the high expense of genetic testing puts it out of reach for routine use in the clinic.
October 30, 2019
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Gemelli Biotech airs validating data for IBS biomarker test
Developed by researchers at Cedars-Sinai Medical Center in Los Angeles and licensed to Gemelli Biotech, the ibs-smart test screens for antibodies to cytolethal distending toxin B (CdtB), a toxin produced by bacteria that cause gastroenteritis, and vinculin, a protein found in the small intestine. Elevated levels of these biomarkers are associated with IBS. Traditionally, doctors had to rule out a range of conditions to make the IBS diagnosis, whereas this test shows with high confidence whether patients actually have the condition, based on the two biomarkers, the company noted.
May 20, 2019
Researchers link protein group to end-stage renal disease
Researchers found that a group of 17 circulating inflammatory proteins were consistently associated with a patient's progression to end-stage renal disease. They believe that the protein group, called the kidney risk inflammatory signature (KRIS), could alert physicians to the chance that a diabetic patient's disease is at risk of progressing.
April 22, 2019
FDA gives nod to Hologic assay for STI bacterium
Called Aptima, it is the first test to be cleared by the FDA for M. genitalium, which is associated with inflammation of the urethra (nongonococcal urethritis) in men and inflammation of the cervix (cervicitis) and infection of the reproductive organs (pelvic inflammatory disease) in women.
January 28, 2019
Page 1 of 1